We recommend using a newer internet browser, such as Google Chrome or Microsoft Edge, to optimize your browsing experience.

Skip to main content

Study of Tiotropium Hydrofluoralkane in Patients With Chronic Obstructive Pulmonary Disease

- Chronic Obstructive Pulmonary Disease | COPD
- Withdrawn

Study Title: A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease

Teva Identifier: TBB-COPD-20009

ClinicalTrials.gov Identifier: NCT02203474

Study Status: Withdrawn

Trial Condition(s): Chronic Obstructive Pulmonary Disease | COPD

Interventions: Drug: Tiotropium HFA BAI 5 mcg | Drug: Tiotropium 18 mcg Capsule | Drug: Placebo

Study Description: Please refer to ClinicalTrials.gov for a description of the trial

ClinicalTrials.gov study records with inclusion and exclusion criteria

Key Participation Requirements

Gender: Female, Male

Age Range: 40 Years to 80 Years

Trial Duration: 08/01/2014 - 08/01/2014

Phase: Phase 2

Study Type

Interventional